文献速递肝病消化道肿瘤与早癌

肝癌监测对代偿期肝硬化患者生存的影响

Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis.
PubMed 文献 · Hepatology · 2018-05-09

本研究构建多状态马尔可夫模型模拟50岁代偿期肝硬化患者队列,评估肝癌监测对全因和肝癌特异性死亡率的影响。无监测时68.2%队列成员15年内死亡,其中25.1%死于肝癌、43.6%死于肝功能失代偿;监测使中位生存期从10.4年提高至11.2年。结论认为肝癌监测可降低代偿期肝硬化患者全因和肿瘤特异性死亡率,与肝移植可及性无关。

要点

  • 无监测时68.2%队列成员15年内死亡,25.1%死于肝癌,43.6%死于肝功能失代偿。
  • 监测使中位生存期从10.4年提高至11.2年。
  • 15年内减少1例全因死亡和1例肝癌特异性死亡所需监测人数分别为28和18。

核心结论

  • 肝癌监测可降低代偿期肝硬化患者全因和肿瘤特异性死亡率,无论肝移植是否可及。
  • 肝癌发病率和监测检测灵敏度对监测获益也有实质性影响。

研究设计与样本

  • 构建多状态马尔可夫模型,模拟50岁代偿期肝硬化患者队列。
  • 主要结局为全因死亡率和肝癌特异性死亡率。
  • 主要输入数据包括肝癌发病率、筛查检测灵敏度和肝功能失代偿死亡率。
  • 模拟的治疗方式包括肝移植、切除和射频消融。
  • 基础情景中,一定比例患者可接受肝移植以避免死亡。

主要发现

  • 无监测时,68.2%队列成员15年内死亡;其中25.1%死于肝癌,43.6%死于肝功能失代偿。
  • 有监测时,中位生存期从10.4年提高至11.2年。
  • 15年内减少1例全因死亡所需监测人数为28,减少1例肝癌特异性死亡所需监测人数为18。
  • 敏感性分析中,肝癌发病率和肝硬化进展对监测获益影响最强,肝移植可及性影响可忽略。

关键数值与推荐

  • 无监测时15年内全因死亡比例为68.2%,其中肝癌死亡占25.1%,肝功能失代偿死亡占43.6%。
  • 监测使中位生存期从10.4年提高至11.2年。
  • 15年内减少1例全因死亡需监测人数为28,减少1例肝癌特异性死亡需监测人数为18。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Surveillance for hepatocellular carcinoma (HCC) has been recommended in patients with cirrhosis. In this study, we examined the extent to which the competing risk of hepatic decompensation influences the benefit of HCC surveillance by investigating the impact of availability of liver transplantation (LTx) and the rate of progression of hepatic decompensation on survival gain from HCC surveillance. A multistate Markov model was constructed simulating a cohort of 50-year-old patients with compensated cirrhosis. The primary outcome of interest was all-cause and HCC-specific mortality. The main input data included incidence of HCC, sensitivity of screening test, and mortality from hepatic decompensation. Treatment modalities modeled included LTx, resection, and radiofrequency ablation. In the base case scenario, LTx would be available to prevent death in a certain proportion of patients. In the absence of surveillance, 68.2% of the cohort members died within 15 years; of these decedents, 25.1% died from HCC and 43.6% died from hepatic decompensation. With surveillance, the median survival improved from 10.4 years to 11.2 years. The number of subjects under surveillance needed to reduce one all-cause and one HCC-specific death over 15 years was 28 and 18, respectively. In sensitivity analyses, incidence of HCC and progression of cirrhosis had the strongest effect on the benefit of surveillance, whereas LTx availability had a negligible effect. CONCLUSION: HCC surveillance decreases all-cause and tumor-specific mortality in patients with compensated cirrhosis regardless of LTx availability. In addition, incidence of HCC and sensitivity of surveillance test also had a substantial impact on the benefits of surveillance. (Hepatology 2018;68:78-88).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Yang JD, Mannalithara A, Piscitello AJ, et al. Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis. Hepatology. 2018. PMID: 29023828. doi:10.1002/hep.29594

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。